Re: How much is life worth: Cetuximab, non-small cell lung cancer, and the $440 billion question

Journal of the National Cancer Institute

Volumn 102, Issue 15, 2010, Pages 1207-

  Cohen, Joshua ^a   Looney, William ^b  

^a TUFTS UNIVERSITY SCHOOL OF MEDICINE   (United States)

^b PFIZER INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CETUXIMAB; GEMCITABINE; OXALIPLATIN; PACLITAXEL; TRASTUZUMAB;

CLINICAL RESEARCH; HEALTH CARE COST; HEALTH CARE MANAGEMENT; HUMAN; LETTER; LUNG NON SMALL CELL CANCER; PRIORITY JOURNAL; QUALITY ADJUSTED LIFE YEAR; REIMBURSEMENT;

ANTIBODIES, MONOCLONAL; ANTINEOPLASTIC AGENTS; CARCINOMA, NON-SMALL-CELL LUNG; COST-BENEFIT ANALYSIS; DRUG COSTS; EVIDENCE-BASED MEDICINE; HUMANS; LUNG NEOPLASMS; OFF-LABEL USE; QUALITY-ADJUSTED LIFE YEARS; REIMBURSEMENT MECHANISMS; UNITED STATES;

EID: 77955445968     PISSN: 00278874     EISSN: 14602105     Source Type: Journal    
DOI: 10.1093/jnci/djq246     Document Type: Letter

References (3)

1. Fojo T, Grady C. How much is life worth: cetuximab, non-small cell lung cancer, and the $440 billion question. J Natl Cancer Inst. 2009; 101 (17): 1044-1048
2. Gafni A, Birch S. Incremental cost-effectiveness ratios (ICERs): the silence of the lambda. Soc Sci Med. 2006; 62 (9): 2091-2100
3. Leveque D. Off-label use of anticancer drugs. Lancet Oncol. 2008; 9 (11): 1102-1107